Dicerna, Novo Nordisk partner to develop novel liver disease therapies

Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to develop RNA interference therapies for liver-related cardiometabolic diseases, according to a press release.
“We are excited to collaborate with Novo Nordisk on this broad research and development effort that extends the reach of our GalXC platform to a wide range of liver cell targets and maximizes our opportunities in serious liver diseases,” Douglas M. Fambrough, PhD, president and CEO of Dicerna, said in the release.
As part of the agreement, Novo Nordisk will have access to Dicerna’s proprietary GalXC RNAi

Source link

Related posts

High-fat diet linked to unfavorable gut microbiota changes


New pathways in development of liver cancer


The Global Paradigm Shift in Screening for Colorectal Cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World